文献速递呼吸道感染呼吸危重症与机械通气

不同SARS-CoV-2变异株疫情期间欧洲经验中心ECMO治疗COVID-19结局比较

Comparative outcomes of extracorporeal membrane oxygenation for COVID-19 delivered in experienced European centres during successive SARS-CoV-2 variant outbreaks (ECMO-SURGES): an international, multicentre, retrospective cohort study.
PubMed 文献 · Lancet Respir Med · 2023-01-11

ECMO-SURGES为国际多中心回顾性队列研究,纳入8个欧洲国家21个经验ECMO中心2020年1月1日至2021年9月30日因COVID-19相关ARDS接受ECMO的连续成人患者1345例。总体90天死亡率为42%,不同变异株粗死亡率相近,但校正混杂因素后delta变异株死亡风险显著高于其他变异株(以野生型为参照)。

要点

  • 总体90天死亡率为42%,各变异株粗死亡率相近。
  • 校正后delta变异株死亡风险显著高于其他变异株。
  • 年龄、免疫抑制、插管延迟、肾替代治疗等为独立死亡预测因素。

核心结论

  • 总体粗死亡率在不同SARS-CoV-2变异株间无差异,但校正后delta变异株感染患者接受ECMO的死亡风险最高。
  • delta株毒力更高、结局更差,可能与病毒载量更高及炎症反应综合征增强有关。
  • 死亡率明显低于其他大型多中心COVID-19 ECMO系列,提示应将资源集中于经验丰富的中心。

研究设计与样本

  • 国际、多中心、回顾性队列研究,纳入8个欧洲国家21个经验ECMO中心的连续成人患者。
  • 纳入2020年1月1日至2021年9月30日实验室确诊SARS-CoV-2感染并因ARDS接受ECMO者,共1345例。
  • 按SARS-CoV-2变异株(野生型、alpha、delta或其他)及大流行时段分组。
  • 采用描述性统计和Kaplan-Meier生存曲线分析特征、管理与结局,用多因素Cox回归确定独立死亡危险因素。

主要发现

  • ECMO启动后90天总死亡率为42%(1345例中569例死亡)。
  • 90天死亡率:野生型43%(297/686)、alpha 39%(152/391)、delta 40%(78/195)、其他变异株(主要为beta和gamma)58%(42/73)。
  • 2020年第二学期野生型仍流行时死亡率为50%,较其他学期(40%)高10%。
  • 独立死亡预测因素包括年龄、免疫抑制状态、ICU入住至插管时间较长、需要肾替代治疗,以及ECMO前较高的SOFA血流动力学分量表评分、动脉血二氧化碳分压和乳酸浓度。
  • 校正上述变量后,delta变异株死亡率显著高于其他变异株,以野生型为参照。

关键数值与推荐

  • 90天死亡率总体42%(569/1345)。
  • 野生型43%(297/686)、alpha 39%(152/391)、delta 40%(78/195)、其他变异株58%(42/73)。
  • 2020年第二学期死亡率50%,其他学期40%。

临床怎么用

  • 应优先将COVID-19相关ARDS患者集中至经验丰富的ECMO中心治疗。
  • 评估ECMO指征时需综合考虑年龄、免疫抑制、插管延迟、肾替代治疗需求及ECMO前SOFA血流动力学评分、PaCO2和乳酸水平。
  • 面对高毒力变异株出现时,应更新ECMO选择标准并提高人群疫苗接种率。

局限性

  • 为回顾性研究设计。
  • 变异株分组中其他变异株样本量较小(73例)。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To inform future research and practice, we aimed to investigate the outcomes of patients who received extracorporeal membrane oxygenation (ECMO) for acute respiratory distress syndrome (ARDS) due to different variants of SARS-CoV-2. METHODS: This retrospective study included consecutive adult patients with laboratory-confirmed SARS-CoV-2 infection who received ECMO for ARDS in 21 experienced ECMO centres in eight European countries (Austria, Belgium, England, France, Germany, Italy, Portugal, and Spain) between Jan 1, 2020, and Sept 30, 2021. We collected data on patient characteristics, clinical status, and management before and after the initiation of ECMO. Participants were grouped according to SARS-CoV-2 variant (wild type, alpha, delta, or other) and period of the pandemic (first [Jan 1-June 30] and second [July 1-Dec 31] semesters of 2020, and first [Jan 1-June 30] and second [July 1-Sept 30] semesters of 2021). Descriptive statistics and Kaplan-Meier survival curves were used to analyse evolving characteristics, management, and patient outcomes over the first 2 years of the pandemic, and independent risk factors of mortality were determined using multivariable Cox regression models. The primary outcome was mortality 90 days after the initiation of ECMO, with follow-up to Dec 30, 2021. FINDINGS: ECMO was initiated in 1345 patients. Patient characteristics and management were similar for the groups of patients infected with different variants, except that those with the delta variant had a younger median age and less hypertension and diabetes. 90-day mortality was 42% (569 of 1345 patients died) overall, and 43% (297/686) in patients infected with wild-type SARS-CoV-2, 39% (152/391) in those with the alpha variant, 40% (78/195) in those with the delta variant, and 58% (42/73) in patients infected with other variants (mainly beta and gamma). Mortality was 10% higher (50%) in the second semester of 2020, when the wild-type variant was still prevailing, than in other semesters (40%). Independent predictors of mortality were age, immunocompromised status, a longer time from intensive care unit admission to intubation, need for renal replacement therapy, and higher Sequential Organ Failure Assessment haemodynamic component score, partial pressure of arterial carbon dioxide, and lactate concentration before ECMO. After adjusting for these variables, mortality was significantly higher with the delta variant than with the other variants, the wild-type strain being the reference. INTERPRETATION: Although crude mortality did not differ between variants, adjusted risk of death was highest for patients treated with ECMO infected with the delta variant of SARS-CoV-2. The higher virulence and poorer outcomes associated with the delta strain might relate to higher viral load and increased inflammatory response syndrome in infected patients, reinforcing the need for a higher rate of vaccination in the population and updated selection criteria for ECMO, should a new and highly virulent strain of SARS-CoV-2 emerge in the future. Mortality was noticeably lower than in other large, multicentre series of patients who received ECMO for COVID-19, highlighting the need to concentrate resources at experienced centres. FUNDING: None.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Schmidt M, Hajage D, Landoll M, et al. Comparative outcomes of extracorporeal membrane oxygenation for COVID-19 delivered in experienced European centres during successive SARS-CoV-2 variant outbreaks (ECMO-SURGES): an international, multicentre, retrospective cohort study. Lancet Respir Med. 2023. PMID: 36640786. doi:10.1016/S2213-2600(22)00438-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。